Acute Gout Clinical Trial
Official title:
Safety & Efficacy of Genakumab in Patients With Frequent Flares
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout
Phase Ib: single arm, open lable, single dose, dose escalation,design. There are 3 dose groups with 10 participant s in each group. Phase II: randomized, double-blind, active control design.There are 2 dose groups of Genakumab for Injection with 30 participant s in each group and 1 group of Compound Betamethasone Injection with 30 praticipants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02674776 -
Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
|
Phase 3 | |
| Not yet recruiting |
NCT05925166 -
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
|
N/A | |
| Completed |
NCT00798369 -
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
|
Phase 2 | |
| Active, not recruiting |
NCT05328531 -
Clinical Study of Genakumab for Injection in Patients With Acute Gout
|
Phase 1/Phase 2 | |
| Completed |
NCT01080131 -
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
|
Phase 3 | |
| Recruiting |
NCT05936268 -
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
|
Phase 2 | |
| Not yet recruiting |
NCT05936281 -
Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy
|
Phase 2 | |
| Recruiting |
NCT05588908 -
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05698680 -
Prednisolone Versus Colchicine for Acute Gout in Primary Care
|
Phase 4 | |
| Completed |
NCT00142558 -
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)
|
Phase 4 | |
| Not yet recruiting |
NCT06169891 -
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
|
Phase 3 | |
| Completed |
NCT01029652 -
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
|
Phase 3 | |
| Withdrawn |
NCT00997581 -
Apremilast Therapy for Acute Gouty Arthritis
|
Phase 2 |